Full-Time
Posted on 7/29/2026
Global biopharmaceutical company developing medicines
$58.7k - $103.5k/yr
Vernon Hills, IL, USA
Hybrid
Hybrid role; on-site work in Mettawa, Illinois.
See people who can refer or advise you
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Flexible Work Hours
Professional Development Budget
AbbVie reported second-quarter revenue of $16.99 billion, up 10.2% year-on-year and exceeding analyst expectations of $16.79 billion. Adjusted earnings per share of $3.65 also beat consensus estimates of $3.61. The pharmaceutical company's growth was driven by its immunology portfolio, particularly SKYRIZI and RINVOQ, and neuroscience products including Vraylar and Vialev. CEO Robert Michael noted each portfolio "delivered growth above 20%". However, AbbVie lowered its full-year adjusted earnings guidance to $13.97 per share at the midpoint, a 1.5% decrease. Management attributed the revision to anticipated dilution from the planned Apogee Therapeutics acquisition and increased research and development spending. The company faces ongoing biosimilar pressure on legacy products whilst pursuing regulatory approvals for new indications and preparing to launch Tevapadon for Parkinson's disease.
AbbVie expects SKYRIZI to generate $21.7 billion of its projected $67.6 billion in 2026 revenue, representing nearly one-third of total sales from a single medicine. The immunology drug sold $5.5 billion in Q2 2026, up 24% operationally, whilst the company's next largest product, RINVOQ, brought in $2.5 billion. The concentration becomes significant as other segments struggle. Oncology revenue fell 2.4% operationally to $1.6 billion, whilst aesthetics slipped 0.9% to $1.3 billion. Neuroscience grew roughly 20% to $3.2 billion. AbbVie's experience with HUMIRA illustrates the biosimilar risk. The former blockbuster fell 36% operationally to $756 million in Q2 2026 due to competition. However, SKYRIZI's US composition-of-matter patent doesn't expire until 2033, with additional patents extending into the mid-2030s. Shares trade at $250.94, up 37% over twelve months, valuing the company at $444 billion.
AbbVie reported strong second-quarter 2026 results, driven by over 20% growth in SKYRIZI, RINVOQ, and its neuroscience portfolio. The company raised its full-year revenue guidance by $300 million. Management expects RINVOQ to reach combined peak sales approaching $2 billion in vitiligo and alopecia areata, significantly above previous projections. The Parkinson's portfolio, including tevapadone, is forecast to exceed $5 billion in peak sales. AbbVie is acquiring Apogee Therapeutics to strengthen its immunology pipeline with long-acting biologics for the 2030s and beyond. The transaction is expected to close in the third quarter. HUMIRA sales declined 36.1% due to biosimilar competition, whilst IMBRUVICA faces pressure from Medicare pricing reforms. The company aims to achieve a net leverage ratio of 2 times within two to three years following the Apogee acquisition.
AbbVie reported second-quarter results that exceeded expectations but reduced its full-year guidance due to a major acquisition. Net revenues climbed 10.2% to $16.99 billion, beating the $16.78 billion estimate. Adjusted diluted earnings reached $3.65 per share, surpassing the $3.60 consensus. The immunology segment grew 15.1% to $8.79 billion, with Skyrizi and Rinvoq each up around 24%. Humira revenues fell 35.9% to $756 million. Neuroscience revenues rose 20.3% to $3.23 billion, whilst oncology declined 1.5% to $1.65 billion. AbbVie lowered its 2026 adjusted earnings per share guidance to a range of $13.87 to $14.07, down $0.04 at the midpoint. The reduction reflects $0.14 per share dilution from the proposed $10.9 billion acquisition of Apogee Therapeutics, expected to close in the third quarter.
AbbVie reported second-quarter revenue of $16.99 billion, beating analyst estimates of $16.79 billion and marking 10.2% year-on-year growth. The pharmaceutical company's non-GAAP earnings of $3.65 per share also exceeded expectations by 1.2%. Operating margin improved to 37.9%, up from 31.7% in the same quarter last year. However, management lowered full-year adjusted EPS guidance to $13.97 at the midpoint, a 1.5% decrease. Over the past two years, AbbVie's revenue has grown at an 8.2% annualised rate. Analysts expect revenue to grow 8.5% over the next 12 months. AbbVie, which spun off from Abbott Laboratories in 2013, develops medications for autoimmune diseases, cancer, and neurological disorders.